Amgen (AMGN) has been through a dynamic phase, experiencing both upward and downward trends in the market. Amid these fluctuations, the stock had some encouraging moments, such as advances surpassing the market's decline and getting approval in the UK for its
small cell lung cancer treatment Tarlatamab. Its Q3 2024 financial results were released, and a
$1 billion manufacturing initiative was revealed in North Carolina. Notably, Piper Sandler Companies reiterated their Overweight rating for Amgen, despite a price target reduction. Amgen’s
Tarlatamab shot resulted in 20% weight loss in an annual study, which was seen as a significant breakthrough. Despite achieving significant results in obesity treatment, the stock suffered a 5% dip. However, analysts regarded Amgen as the
best safe stock to buy. Amgen presented positive
Phase 3 data for its drug Uplizna in treating myasthenia gravis, and its
dividend was raised to $2.38. The drug company is now gearing up for a
conference to discuss new top-line data in inflammation and rare disease and announced both Q1 and Q4 2024 financial results. Despite such advancements, especially the promising results in the
obesity drug research, Amgen faced market skepticism leading to a 7% stock decrease due to perceived ‘unknown risk’. Amgen’s
Q3 2024 earnings beat estimates, and its muscular disorder drug achieved the primary goal in a late-stage study.
Amgen AMGN News Analytics from Thu, 02 May 2024 07:00:00 GMT to Fri, 03 Jan 2025 21:39:00 GMT -
Rating 6
- Innovation 8
- Information 8
- Rumor -2
